Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31004070 | 1.00 | EGFR (1.00) | EGFR | |
| SCHEMBL20865211 | 1.00 | EGFR (1.00) | EGFR | |
| SCHEMBL24329439 | 0.95 | EGFR (0.91) | EGFR | |
| SCHEMBL24329506 | 0.93 | EGFR (0.87) | EGFR | |
| SCHEMBL20865297 | 0.88 | EGFR (1.00) | EGFR | |
| SCHEMBL20865247 | 0.86 | EGFR (1.00) | EGFR | |
| SCHEMBL20865372 | 0.86 | EGFR (1.00) | EGFR | |
| SCHEMBL22427546 | 0.86 | EGFR (0.78) | EGFR | |
| SCHEMBL20865303 | 0.86 | EGFR (1.00) | EGFR | |
| SCHEMBL20865232 | 0.85 | EGFR (0.74) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118987016-A | Application of antisense oligonucleotide in preparing medicament for treating glioma | 北京悦康科创医药科技股份有限公司 | 2024-11-22 | — | — | CN | claimed |
| WO-2022020114-A2 | METHODS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | TING THERAPEUTICS LLC (US) | 2022-01-27 | — | — | WO | claimed |
| US-20250236596-A1 | HYDROXYLAMINE-BASED EGFR INHIBITORS FOR TREATMENT OF CANCER WITH BRAIN METASTASES | UNIV GEORGIA (US) | 2025-07-24 | — | — | US | disclosed |
| EP-4587017-A2 | HYDROXYLAMINE-BASED EGFR INHIBITORS FOR TREATMENT OF CANCER WITH BRAIN METASTASES | University of Georgia Research Foundation, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-4578457-A1 | PHARMACEUTICAL FOR TREATING AND/OR PREVENTING CANCER | Toray Industries, Inc. (JP) | 2025-07-02 | — | — | EP | disclosed |
| CN-119894510-A | Hydroxylamine-based EGFR inhibitors for the treatment of brain metastasis | 乔治亚大学研究基金会 | 2025-04-25 | — | — | CN | disclosed |
| CN-119768182-A | Medicine for treating and/or preventing cancer | 东丽株式会社 | 2025-04-04 | — | — | CN | disclosed |
| WO-2024215467-A9 | METHODS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | TING THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| CN-118987016-A | Application of antisense oligonucleotide in preparing medicament for treating glioma | 北京悦康科创医药科技股份有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20240350492-A1 | Methods for the Prevention and Treatment of Hearing Loss | TING THERAPEUTICS LLC (US) | 2024-10-24 | — | — | US | disclosed |
| WO-2024215467-A1 | METHODS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | TING THERAPEUTICS LLC (US) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024059668-A2 | HYDROXYLAMINE-BASED EGFR INHIBITORS FOR TREATMENT OF CANCER WITH BRAIN METASTASES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024043252-A1 | PHARMACEUTICAL FOR TREATING AND/OR PREVENTING CANCER | 東レ株式会社 | 2024-02-29 | — | — | WO | disclosed |
| WO-2022020114-A2 | METHODS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | TING THERAPEUTICS LLC (US) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236596-A1 | HYDROXYLAMINE-BASED EGFR INHIBITORS FOR TREATMENT OF CANCER WITH BRAIN METASTASES | EGFR, ERBB2, ERBB3 | EGFR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.